NSRX

Nasus Pharma Ltd. (NSRX) ESG Analysis Analysis (2026)

Invetso Score: 5.4/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.0 (Moderate)

NSRX provides no disclosed environmental intensity metrics in the supplied data, leaving its peer-relative emissions and resource-use positioning difficult to verify versus more transparent peers.

Zero reported R&D-to-revenue does not indicate environmental leadership, and peers with disclosed clean-technology investment typically demonstrate clearer transition readiness.

The absence of disclosed gross profit margin and free cash flow data limits assessment of capital available for environmental compliance, unlike peers with fuller sustainability reporting.

No Tier 1 filing evidence was provided on energy use, emissions, or waste, so the company cannot be credited with a stronger environmental profile than reporting peers.

Social

Score:

No disclosed workforce, safety, or human-capital metrics were provided, which weakens peer-relative visibility on labor practices compared with companies that report these indicators.

Zero stock-based compensation to revenue suggests limited equity-linked retention intensity, but it does not by itself establish stronger employee alignment than peers.

The lack of controversy or incident data prevents assigning a materially weaker social score, yet the company also lacks evidence of superior social management versus peers.

Without filing-based disclosure on diversity, training, or community impacts, NSRX remains broadly middle-tier relative to peers with more complete social reporting.

Governance

Score:

Debt-to-equity of 0.009 and net debt-to-EBITDA of 1.07 indicate conservative leverage, which generally reduces creditor pressure and supports governance flexibility versus more levered peers.

Very low leverage can also reflect limited external discipline, so the governance advantage is modest rather than structural relative to stronger board-oversight peers.

No filing evidence was provided on board independence, audit quality, or shareholder rights, preventing a higher governance score despite the balance-sheet conservatism.

The absence of reported stock-based compensation reduces dilution concerns, but peer leaders usually pair that with clearer governance disclosure and oversight practices.

Overall Score

Score:

NSRX ranks as a middle-tier ESG name versus peers because limited disclosure constrains evidence of leadership, while leverage discipline provides only a modest governance offset.

Score Driver: Limited ESG Disclosure Versus Peers

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Nasus Pharma Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →